S. Shrivastav

发表

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma

M. Berger, M. McDermott, P. Theodosopoulos, 2015, Journal of Neuro-Oncology.

Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy

H. Okada, M. Aghi, G. Yagnik, 2017, Oncogene.

Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy

M. Mann, K. Garcia, J. Sidney, 2018, The Journal of experimental medicine.

Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas

J. Costello, R. Warta, H. Okada, 2017, The Journal of clinical investigation.

IDH mutation-induced suppression of type-1 anti-glioma immune response

J. Costello, H. Okada, G. Kohanbash, 2015, Journal of Immunotherapy for Cancer.

Novel and shared neoantigen for glioma T cell therapy derived from histone 3 variant H3.3 K27M mutation

I. Pollack, S. Mueller, H. Okada, 2015, Journal of Immunotherapy for Cancer.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Isocitrate dehydrogenase mutations suppress STAT 1 and CD 8 + T cell accumulation in gliomas

H. Okada, T. Mazor, G. Kohanbash, 2022 .

MTR-01BEVACIZUMAB-INDUCED MIF DEPLETION: A NOVEL RESISTANCE MECHANISM IN GLIOBLASTOMA.

H. Okada, M. Aghi, G. Kohanbash, 2015 .